- Home
- RIGL vs CARE Comparison
RIGL vs CARE Comparison
Compare RIGL & CARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- CARE
- Stock Information
- Founded
- RIGL 1996
- CARE 1974
- Country
- RIGL United States
- CARE United States
- Employees
- RIGL N/A
- CARE N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- CARE Major Banks
- Sector
- RIGL Health Care
- CARE Finance
- Exchange
- RIGL Nasdaq
- CARE Nasdaq
- Market Cap
- RIGL 335.5M
- CARE 396.9M
- IPO Year
- RIGL 2000
- CARE N/A
- Fundamental
- Price
- RIGL $38.85
- CARE $19.46
- Analyst Decision
- RIGL Buy
- CARE Buy
- Analyst Count
- RIGL 5
- CARE 2
- Target Price
- RIGL $38.20
- CARE $21.50
- AVG Volume (30 Days)
- RIGL 995.6K
- CARE 71.3K
- Earning Date
- RIGL 08-05-2025
- CARE 10-23-2025
- Dividend Yield
- RIGL N/A
- CARE N/A
- EPS Growth
- RIGL N/A
- CARE 154.06
- EPS
- RIGL 5.43
- CARE 1.36
- Revenue
- RIGL $267,921,000.00
- CARE $153,120,000.00
- Revenue This Year
- RIGL $59.93
- CARE $10.85
- Revenue Next Year
- RIGL N/A
- CARE $14.12
- P/E Ratio
- RIGL $7.15
- CARE $14.31
- Revenue Growth
- RIGL 105.62
- CARE 21.78
- 52 Week Low
- RIGL $12.66
- CARE $13.61
- 52 Week High
- RIGL $43.72
- CARE $20.40
- Technical
- Relative Strength Index (RSI)
- RIGL 68.57
- CARE 70.53
- Support Level
- RIGL $39.00
- CARE $18.42
- Resistance Level
- RIGL $42.08
- CARE $19.80
- Average True Range (ATR)
- RIGL 2.32
- CARE 0.43
- MACD
- RIGL -0.37
- CARE 0.11
- Stochastic Oscillator
- RIGL 53.26
- CARE 84.04
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About CARE Carter Bankshares Inc.
Carter Bankshares Inc is a bank holding company that conducts its business solely through the bank. The Bank earns revenue from interest on loans and securities and fees charged for financial services provided to customers. It offers a full range of deposit services including Lifetime Free Checking, interest checking accounts, savings accounts, retirement accounts and other deposit accounts of various types, ranging from money market accounts to longer-term CDs. The Bank offers a full range of commercial and consumer loans. The Bank also originates and holds fixed and variable-rate mortgage loans and offers home equity lines of credit to its customers.